Yes, tirzepatide significantly reduces appetite and energy intake by activating GLP-1 and GIP receptors, which help regulate hunger, metabolism, and insulin response. This dual action slows stomach emptying, enhances fullness, and decreases cravings, leading to lower calorie intake and sustainable weight loss. Additionally, tirzepatide influences brain signals that control appetite, reducing snacking and promoting better portion control. Studies have shown that individuals on tirzepatide consume fewer calories and experience greater weight loss compared to other treatments. By optimizing how the body processes food, tirzepatide supports fat burning while preserving muscle mass, making it a powerful option for long-term weight management.
Further Reading:
1. Heise, Tim, et al. “Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with Type 2 Diabetes.” Diabetes Care, 1 Mar. 2023. https://doi.org/10.2337/dc22-1710.
2. Aronne, Louis J., et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA, 11 Dec. 2023. jamanetwork.com/journals/jama/fullarticle/2812936, https://doi.org/10.1001/jama.2023.24945.
3. Nauck, Michael A., and David A. D’Alessio. “Tirzepatide, a Dual GIP/GLP-1 Receptor Co-Agonist for the Treatment of Type 2 Diabetes with Unmatched Effectiveness Regarding Glycaemic Control and Body Weight Reduction.” Cardiovascular Diabetology, vol. 21, no. 1, 1 Sept. 2022, p. 169. pubmed.ncbi.nlm.nih.gov/36050763/, https://doi.org/10.1186/s12933-022-01604-7.